

Supporting Information for

Targeting and self-assembling peptides mimic fibrinogen coagulation for alleviating hypofibrinogenemia

Gui-Yuan Wang^{a,c,d,e,1}, Zhuo-Yue Li^{b,c,1}, Chao-Ran Li^{a,c,d,1}, Ya-Tao Wang^{a,c,d,1}, Pei-Pei Yang^{c,*}, Lei Wang^c, Hao Wang^c, Xu Cui^d and Litao Li^{d,*}

^aGraduate School of Hebei North University, No. 11 Diamond South Road, Economic Development Zone, Zhangjiakou, 075000, Hebei Province, China

^bCollege of Medicine, Southwest Jiaotong University, No. 111 Beiyiduan, Second Ring Road, Chengdu, 610031, Sichuan Province, China

^cCAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China

^dSenior Department of Orthopedics, Chinese PLA General Hospital, No. 51, Fucheng Road, Haidian District, Beijing, 100048

^eThe Second Affiliated Hospital of Xingtai Medical College, No. 376 Shunde Road, Xingtai, 054001, Hebei Province, China

¹These authors contributed equally to this work.

E-mail addresses: yangpp@nanoctr.cn, lltop_1@sina.com




Figure S1. The molecular structure and MALDI-TOF-MS spectra of a) SC₁₂FS, b) SC₁₂GS, c) C₁₂GS.




Figure S2. TEM images of C₁₂FS, SC₁₂GS and SC₁₂FS (40 μM) in PBS at different time points. Scale bars, 200 nm.




Figure S3. CD spectra of a) $C_{12}FS$, b) $SC_{12}GS$ and c) $SC_{12}FS$ in water/HFIP (v/v = 99/1) at different time points.




Figure S4. FTIR spectra of $SC_{12}FS$ (30 μM) incubated with platelets at 0 h and 4 h.




Figure S5. UV-vis spectra of SC₁₂FS (30 μM) incubated with platelets at 0 h and 4 h.




Figure S6. a) Zeta potential of SC₁₂FS triggered by platelets at initial (0 h) and final state (4 h) in water.




Figure S7. Zeta Potential of $C_{12}FS$ triggered by platelets at initial (0 h) and final state (4 h) in water.




Figure S8. Zeta potential of SC₁₂GS triggered by platelets at initial (0 h) and final state (4 h) in water.




Figure S9. Cell viability of HUVECs cells treated with different concentrations of a) SC₁₂FS, b) C₁₂GS and c) SC₁₂GS.




Figure S10. The in vivo circulation half-life of the peptide SC₁₂FS was determined in male Kunming mice (6-8 weeks old) by measuring its concentration at 0.25, 1, 4, 8, 24, 48, and 72 hours post-administration.




Figure S11. H&E staining of the heart, liver, spleen, and kidney of tissue slices, after 0.5 h of treatment administration of 6-8 weeks old male Kunming mice.




Figure S12. H&E staining of the heart, liver, spleen, and kidney tissue slices, after 3 d of treatment administration of 6-8 weeks old male Kunming mice.